Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
173 results about "S-Adenosyl methionine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
S-Adenosyl methionine is a common cosubstrate involved in methyl group transfers, transsulfuration, and aminopropylation. Although these anabolic reactions occur throughout the body, most SAM-e is produced and consumed in the liver. More than 40 methyl transfers from SAM-e are known, to various substrates such as nucleic acids, proteins, lipids and secondary metabolites. It is made from adenosine triphosphate (ATP) and methionine by methionine adenosyltransferase (EC 2.5.1.6). SAM was first discovered by Giulio Cantoni in 1952.
Method for protecting humans against superficial vasodilator flush syndrome,
InactiveUS20090148543A1Significant timeImprove the level ofAntibacterial agentsBiocideSulfate proteoglycanS-Adenosyl-l-methionine
Methods for protection of a human from SVFS comprise the administration of a flavonoid compound of the basic structures 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, alone or, optionally, together with one or more of an olive kernel extract, a non-bovine sulfated proteoglycan, bitter willow extract, a D-hexosamine sulfate, S-adenosylmethionine, folic acid, vitamin B12 and a serotonin inhibitor. Such treatment prevents, reduces or eliminates SVFS in patients receiving as much as 300-3000 mg / day of niacin therapeutically, whether administered prior to, or along with, an anti-SVFS composition.
Owner:THETA BIOMEDICAL CONSULTING & DEVMENT
Novel soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same
InactiveUS20020164369A1Easy to handleReadily availableBiocideSugar derivativesS-Adenosyl methionineGelatin film
The invention provides a novel soft gelatin capsule comprising a fill material consisting essentially of S-adenosylmethionine (SAMe) salt disposed within an enteric coated soft gelatin film.
Owner:ORCHID CHEM & PHARM LTD
Recombinant enzyme with altered feedback sensitivity
The present invention relates to the use of recombinant homoserine transsuccinylase enzymes with altered feedback sensitivity (MetA*) and possibly recombinant S-adenosyl methionine synthetase enzymes with reduced activity (MetK*) for the production of methionine, its precursors or derivatives thereof.
Owner:METABOLIC EXPLORER
Anti-inflammatory compositions for treating multiple sclerosis
Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biochemicals from the activated mast cells, the compositions containg one or more of a flavone or flavonoid glycoside a heavily sulfated, non-bovine proteoglycan, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, a hexosamine sulfate such as D-glucosamine sulfate, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, a long-chain unsaturated fatty acid, a phospholipid, Krill oil, a polyamine, glutiramer acetate and interferon. Certain of the present compositions are useful in protecting against the neuropathological components of multiple sclerosis and similar inflammatory neurological diseases.
Owner:THETA BIOMEDICAL CONSULTING & DEVMENT
Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
InactiveUS20090088404A1Act quicklyReduce riskBiocideNervous disorderS-Adenosyl-l-methioninePharmaceutical formulation
Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia.
Owner:METILEJSHN SAJENSIS INT SRL
Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples
This invention pertains to a method for detecting a compound in the presence of other compounds that are substantially similar in structure and metabolically related to the analyte. The invention is particularly suited for the detection of S-adenosylmethionine in the presence of S-adenosylhomocysteine, other nucleosides and derivatives in a biological sample. The methods of this invention involve an antibody produced specifically against S-adenosylmethionine; particularly, analogs modified strategically at the sulfonium position. An assay protocol comprises chemically modified analyte analog linked to an enzymatic reporter and the aforementioned antibody was used to demonstrate the assay specificity and sensitivity. Additional assay method with immobilized immunogen, the specific antibody, and an enzyme labeled secondary antibody was also described for illustration. The invention also features hapten design and novel compounds used as haptens to prepare immunogen and for the specific antibody production.
Owner:HAO XIUJUAN
Topical formulations for the treatment of depression with S adenosyl methionine
InactiveUS20060069059A1BiocideCarbohydrate active ingredientsHigh concentrationS-Adenosyl methionine
Disclosed herein are topical formulations for treating depression with S adenosyl methionine (SAM-e) The topical formulations contain at least 35% wt / wt of SAM-e partially dissolved in aqueous and lipophilic phases of an emulsion and the emulsion is stable from separation of phases for a period of at least 30 days despite the high concentration of SAM-e. Also provided are methods for making such compositions and methods of treating depression using the same.
Owner:JAMES L SCHALLER M D P A
Anti-inflammatory composition for treating pelvic endometriosis
InactiveUS20050220912A1Promote absorptionBiocideCarbohydrate active ingredientsDiseaseChondroitin Sulfate C
Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, an unrefined olive kernel oil / extract that increases absorption of these compositions in various routes of administration, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.
Owner:THETA BIOMEDICAL CONSULTING & DEVMENT
Use of anabolic agents, anti-catabolic agents, antioxidant agents and analgesics for protection, treatment and repair of connective tissues in humans and animals
InactiveUS20090087503A1Repair and treat and prevent damageBiocideElcosanoid active ingredientsSuper oxide dismutaseS-Adenosyl methionine
The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado / soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.
Owner:NUTRAMAX LABORATORIES INC
Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same
InactiveUS6759395B2Easy to swallowGood optionBiocideSugar derivativesS-Adenosyl methionineGelatin film
The invention provides a novel soft gelatin capsule comprising a fill material consisting essentially of S-adenosylmethionine (SAMe) salt disposed within an enteric coated soft gelatin film.
Owner:ORCHID CHEM & PHARM LTD
Synergistic proteoglycan compositions for inflammatory conditions
Owner:THETA BIOMEDICAL CONSULTING & DEVMENT
Biofuel and chemical production by recombinant microorganisms via fermentation of proteinacious biomass
Provided herein are metabolically modified microorganisms characterized by having an increased keto-acid flux when compared with the wild-type organism and comprising at least one polynucleotide encoding an enzyme, and causing the production of a greater quantity of a chemical product when compared with the wild-type organism. The recombinant microorganisms are useful for producing a large number of chemical compositions from various nitrogen containing biomass compositions and other carbon sources. More specifically, provided herein are methods of producing alcohols, acetaldehyde, acetate, isobutyraldehyde, isobutyric acid, n- butyraldehyde, n-butyric acid, 2-methyl-l-butyraldehyde, 2-methyl-l -butyric acid, 3- methyl-l-butyraldehyde, 3 -methyl- 1 -butyric acid, ammonia, ammonium, amino acids, 2,3-butanediol, 1,4-butanediol, 2-methyl-l, 4-butanediol, 2-methyl- 1,4-butanediamine, isobutene, itaconate, acetoin, acetone, isobutene, 1,5-diaminopentane, L-lactic acid, D- lactic acid, shikimic acid, mevalonate, polyhydroxybutyrate (PHB), isoprenoids, fatty acids, homoalanine, 4-aminobutyric acid (GABA), succinic acid, malic acid, citric acid, adipic acid, p-hydroxy-cinnamic acid, tetrahydrofuran, 3-methyl-tetrahydrofuran, gamma-butyrolactone, pyrrolidinone, n-methylpyrrolidone, aspartic acid, lysine, cadeverine, 2-ketoadipic acid, and / or S-adenosyl-methionine (SAM), from a suitable nitrogen rich biomass.
Owner:RGT UNIV OF CALIFORNIA
BIO-REPLENISHMENT (BioRep) FOR IMPROVING SLEEP ARCHITECTURE
InactiveUS20130064804A1Easy to pumpGood curative effectOrganic active ingredientsNervous disorderSleep architectureS-Adenosyl methionine
Methods to prepare a bio-replenishment (BioRep) with specific combinations of S-adenosylmethionine (SAMe), lactoferrin (LF) and ribonuclease (RNAse) to restore regular sleep pattern are described. Additionally, compositions of functional delivery systems that recreate both alternate phases of non-rapid eye movement (NREM) and rapid eye movement (REM) sleep cycles are disclosed. These methods and compositions have implications in the clinical management of various sleep disorders including insomnia, circadian rhythm disorders and obstructive sleep apnea.
Owner:NAIDU LP
Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
InactiveUS20070141181A1Repair and treat and prevent damageBiocideAntipyreticSuper oxide dismutaseS-Adenosyl-l-methionine
The present invention relates to compositions for the modulation of inflammation in connective tissues in humans and animals and the modulation of markers of such inflammation, including COX-2, TNF-α, IL-1β, iNOS, p38, and chemokines, comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothioneine, methylsulfanylmethane, one or more avocado / soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.
Owner:NUTRAMAX LABORATORIES INC
Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
InactiveUS20090197824A1Act quicklyReduce riskBiocideNervous disorderS-Adenosyl-l-methioninePharmaceutical formulation
Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia.
Owner:METILEJSHN SAJENSIS INT SRL
Method for preparing S-adenomethionine
InactiveCN101230373ACoupled realizationLow costMicroorganism based processesFermentationPhosphate ionMaltose
The invention discloses a method of preparing S-adenosyl methionine, according to the method, by using polyhydroxyl organic reagent to keep the activity of enzyme, by taking adenosine triphosphate precursor, L-methionine and phosphate ions as a substrate and taking glucose and / or Maltose as an energy supplier, and by adding the combination of metal ions, the producing strain with permeability can be used for producing S-adenosyl methionine in the way of whole-cell biocatalysis. The invention can use the combination of metal ions to regulate the metabolism flow to improve energy self-coupling efficiency; and organic reagent is added to keep the activities of thalli and enzyme. The strain with permeability is used for producing S-adenosyl methionine, thereby shortening the synthesis time and accumulating outcomes outside cells, so that the cost of the following separation can be reduced, and the operational steps also can be simplified.
Owner:NANJING UNIV OF TECH
Molecular markers of hepatocellular carcinoma and their applications
InactiveUS20090181379A1Precise definitionFacilitate prognosisCompound screeningApoptosis detectionEtiologyProteomics methods
By means of a proteomic approach, the markers of hepatocellular carcinoma (HCC) in the liver of a knockout mouse (MAT1A− / −) have been identified for the MAT1A gene (deficient in the synthesis of S-adenosylmethionine). 27 proteins have been detected the expression thereof is altered in, at least, 50% of the analysed tumours. Amongst them, 13 proteins have been validated in biopsies of patients with HCC of different etiology, and 7 of them have been validated in biopsies of patients with liver cirrhosis, a stage prior to the development of HCC, which makes it possible to differentiate between prior stages of the disease and even between different etiologies (viral and alcoholic). Having a panel of markers available may contribute to more accurately defining the alterations associated with the development of HCC and thus facilitate prognosis and diagnosis of this disease.
Owner:PROYECTO DE BIOMEDICINA CIMA
S-adenosylmethionine formulations with enhanced bioavailability
InactiveUS20110027342A1Reduce penetrationPromote absorptionBiocideNervous disorderImmunologic disordersS-Adenosyl-l-methionine
The invention relates to compositions and methods to enhance the absorption of S-adenosylmethionine (SAMe) and to methods of treating various disorders or diseases using non-parenteral SAMe formulations with enhanced-absorption and improved bioavailability. The enhanced bioavailability formulations may be used to treat a variety of diseases or disorders, such as for example, psychiatric disorders including, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, depressive disorders (e.g. major clinical depression) and dysthymia; as well as treating liver disorders, cancer, autoimmune disorders, inflammatory disorders, joint disorders, gastrointestinal disorders and cardiovascular disease.
Owner:MSI METHYLATION SCI
Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples
This invention pertains to a method for detecting a compound in the presence of other compounds that are substantially similar in structure and metabolically related to the analyte. The invention is particularly suited for the detection of S-adenosylmethionine in the presence of S-adenosylhomocysteine, other nucleosides and derivatives in a biological sample. The methods of this invention involve an antibody produced specifically against S-adenosylmethionine; particularly, analogs modified strategically at the sulfonium position. An assay protocol comprises chemically modified analyte analog linked to an enzymatic reporter and the aforementioned antibody was used to demonstrate the assay specificity and sensitivity. Additional assay method with immobilized immunogen, the specific antibody, and an enzyme labeled secondary antibody was also described for illustration. The invention also features hapten design and novel compounds used as haptens to prepare immunogen and for the specific antibody production.
Owner:HAO XIUJUAN
Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use
InactiveUS20070161007A1Sugar derivativesMicrobiological testing/measurementS-Adenosyl methionineS-Adenosyl-l-methionine
The present invention discloses compounds and methods used to specifically target substrates of methylation by S-adenosyl-L-methionine (SAM)-dependent methyltransferases. The substrates can be peptides, single stranded nucleic acids or double stranded nucleic acids, including RNA, DNA and PNA or phospholipids. The compounds disclosed are SAM analogs that are ligated to a methylation site by the methyltransferase. Also disclosed, are reacting groups that are ligatable to the cofactor analogs and can also be used as detectable labels. The reacting group can be used to cleave the substrate providing a methylation footprint. The invention can be used clinically to determine methylation state of a gene or gene promoter such as those involved in imprinting and transcription. In some preferred embodiments, the invention includes a kit, which can include one or more suitable SAM analogs and may include one or more detectable labels. In other preferred embodiments, the invention includes a pharmaceutical composition.
Owner:WISCONSIN ALUMNI RES FOUND
Antialcoholismic composition and preparation method thereof
ActiveCN102038867APromote alcohol metabolismReduce absorptionNervous disorderHeterocyclic compound active ingredientsMonkshoodsAlcoholisms
The invention relates to the field of medicaments and discloses an antialcoholismic composition. The raw materials of the antialcoholismic composition comprise: one or a mixture of more than two of S-adenosyl methionine, cysteine and methionine, one of a mixture of D-glyceric acid and D-glycerate, one or a mixture of more than two of succinic acid, fumaric acid, citric acid, oxaloacetic acid and malic acid, one or a mixture of more than two of vitamin B1, vitamin B6 and vitamin B2, one or a mixture of coenzyme Q10 or coenzyme I, L-glutamine, fortune eupatorium herb, artemisia capillaries, white paeony root and root of tall monkshood. The invention also provides a preparation method of the antialcoholismic composition. The antialcoholismic composition disclosed by the invention is taken after wine drinking for reducing absorption of alcohol, accelerating alcohol metabolism, as well as tonifying stomach and spleen and preventing drunkenness and alcoholism. The antialcoholismic composition is quick in effectiveness and has a bright application prospect.
Owner:BEIJING ADINOVO TECH
Proteoglycan compositions for the treatment of cardiovascular inflammatory diseases
InactiveUS7115278B2Promote absorptionBiocideCarbohydrate active ingredientsChondroitin Sulfate CDisease cause
Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, an unrefined kernel olive oil that increases absorption of these compositions in various routes of administration, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.
Owner:THETA BIOMEDICAL CONSULTING & DEVMENT
Transformed fungus having enhanced ergothioneine productivity and method for producing ergothioneine
The purpose of the present invention is to provide an organism having an ergothioneine productivity that is capable of easily producing ergothioneine within a short period of time at a high yield, as compared with a conventional technology, and, therefore, enables ergothioneine production on an industrial scale. This purpose can be achieved by a transformed fungus into which a gene encoding enzyme (1) or genes encoding enzymes (1) and (2) have been inserted and in which the inserted gene(s) are overexpressed. (1) An enzyme catalyzing a reaction of synthesizing hercynyl cysteine sulfoxide from histidine and cysteine in the presence of S-adenosyl methionine, iron (II) and oxygen. (2) An enzyme catalyzing a reaction of synthesizing ergothioneine from hercynyl cysteine sulfoxide using pyridoxal 5'-phosphate as a coenzyme.
Owner:KIKKOMAN CORP
L-ergothioneine, milk thistle, and S-adenosylmethionine for the prevention, treatment and repair of liver damage
This invention provides therapeutic compositions and combinations for the protection, treatment and repair of liver tissue. The invention relates to novel compositions and combinations comprising two or more compounds selected from the group consisting of S-adenosylmethionine, L-ergothioneine, and a substance selected from the group consisting of constituents of Milk thistle (Silybum marianum), silymarin and active components of silymarin, whether naturally, synthetically, or semi-synthetically derived, and to methods of preventing and treating liver disease and of repairing damaged liver tissue. The invention also provides a method of administering these compositions and combinations to humans or animals in need thereof.
Owner:NUTRAMAX LABORATORIES INC
Preparation method and applications of S-adenosylmethionine molecular imprinting sensor
InactiveCN103954675AHigh affinityHigh selectivityMaterial electrochemical variablesS-Adenosyl methionineS-Adenosyl-l-methionine
The invention discloses a preparation method and applications of an S-adenosylmethionine molecular imprinting sensor. The preparation method is characterized by comprising the following steps: firstly modifying a glass-carbon electrode by using nanogold and carbon nano-tubes; successfully researching an imprinting electrochemical sensor with the specific selectivity on the surface of the glass-carbon electrode modified by using the nanogold and the carbon nano-tubes by combining a sol-gel imprinting technology, a layer-by-layer self-assembly method and an electric polymerization method. The S-adenosylmethionine molecular imprinting sensor prepared by adopting the method disclosed by the invention is greatly improved in response, shows the relatively high affinity and selectivity on S-adenosylmethionine forms a sensor which can specifically identify template molecules by being connected with an electrochemical work station and has the advantages of low cost, high sensitivity, good specificity, fastness in detection and repeatability in use.
Owner:UNIV OF JINAN
Compositions and methods for treating depression
Owner:HEDONIAUSA INC
Energy saving brewing method
ActiveUS20130095207A1Reduce energy inputReduce energy consumptionWort preparationBeer fermentationS-Adenosyl methionineS-Adenosyl-l-methionine
Barley based beverages are produced in large quantities, employing highly energy consuming methods, for example in the malting and brewhouse facilities for kiln drying and wort boiling operations, respectively. The present invention relates to energy saving methods for preparing barley based beverages, as well as to barley plants useful in such methods. In particular, the invention describes barley plants with combined traits of null-lipoxygenase-1 (null-LOX-1), null-lipoxygenase-2 (null-LOX-2) and null-S-adenosylmethionine:methionine S-methyltransferase in one plant, which is particularly useful for energy saving methods to prepare barley based beverages, such as beer.
Owner:CARLSBERG BREWERIES AS +1
Universal methylation profiling methods
InactiveUS20110177508A1Sugar derivativesMicrobiological testing/measurementS-Adenosyl methionineS-Adenosyl-l-methionine
This invention provides methods of derivatizing a double-stranded DNA comprising contacting double-stranded DNA with a CpG methyltransferase and an s-adenosylmethionine analog. This invention also provides methods of sequencing DNA to determine methylation patterns. This invention also provides neobases and methods of sequencing for methylation patterns using neobases.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
InactiveUS20170273926A1Low mutation rateShorten the progressPharmaceutical delivery mechanismAmide active ingredientsWho gradePolyamine transport
Eflornithine is an agent that can be used to treat glioma, especially glioma of WHO Grade II or Grade III such as anaplastic glioma. Eflornithine can suppress or prevent mutations in glioma which can cause the glioma to progress to a higher grade. Compositions and methods can include eflornithine or a derivative or analog of eflornithine, together with other agents such as conventional anti-neoplastic agents for treatment of glioma, inhibitors of polyamine transport, polyamine analogs, or S-adenosylmethionine decarboxylase inhibitors.
Owner:ORBUS THERAPEUTICS INC
Method for synthesizing ferulic acid through enzyme method
InactiveCN104818300ASimple processMild reaction conditionsTransferasesFermentationEscherichia coliS-Adenosyl-l-methionine
The present invention discloses a method for synthesizing ferulic acid through an enzyme method, wherein the methyl on S-adenosyl methionine (SAM) is transferred onto caffeic acid so as to finally form the product ferulic acid. The method comprises: a) highly expressing ligusticum chuanxiong hort caffeic acid-O methyltransferase(COMT) through fermentation of escherichia coli, collecting bacteria through centrifugation, re-suspending the bacteria with a Tris-HCl buffer solution, and carrying out ultrasonic bacterial lysis to obtain a mixed enzyme solution containing the ligusticum chuanxiong hort COMT; and b) transferring the methyl provided by SAM to the caffeic acid through the ligusticum chuanxiong hort COMT obtained in the step a), and finally converting into the ferulic acid. The method of the present invention has advantages of simple process, mild reaction condition, high conversion efficiency, low conversion cost, and the like.
Owner:SOUTHWEST JIAOTONG UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com